Are your trial participants taking their meds as prescribed? Schedule a consultation with me to determine whether the tell-tale signs of poor adherence are present, and what you can do about it.
Bernard Vrijens, Scientific Lead, AARDEX Group
During my time in the adherence research space, I have amassed an incredible amount of evidence supporting the fact that poor adherence is prevalent in phase II/III clinical trials. Unfortunately, many sponsors don't realize that it's a problem before it's too late.
Schedule a complimentary adherence review with me and we can chat about:
Complete the form below and I'll follow up to schedule a review at a mutually convenient time.